Rare diseases
Investigational molecules
Locations
Back to Finland9 clinical trials in Lahti, Finland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FinlandKliinisetTutkimukset.fi(opens in a new tab)Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
FinlandEvaluating the effect of recombinant varicella zoster virus glycoprotein E on the risk of dementia in adults aged 76 years and older
FinlandStudy Comparing Intravenous Contrast CT with Non-Contrast CT for Patients with Acute Abdominal Pain and Reduced Kidney Function Using Iohexol
FinlandStudy on the Effects of Fluorouracil and Capecitabine in Patients with Metastatic Colorectal Cancer
FinlandPrevention of Infantile Spasms with Vigabatrin in High-Risk Children Under 1 Year Old: A Study for Patients with Tuberous Sclerosis or Large Vascular Brain Injury
FinlandStudy on Apixaban for Preventing Stroke in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease
FinlandStudy on Fecal Microbiota Transplantation with Infliximab and Vedolizumab for Patients with Ulcerative Colitis
FinlandStudy on Moxifloxacin for Treating Uncomplicated Acute Appendicitis in Adults
FinlandStudy of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety
FinlandThe busiest research cities in the country
What the registry says about research in the country
Innovative studies exploring the effectiveness of contrast-enhanced CT scanning versus native CT in patients with acute abdominal conditions and compromised renal function.
Research focusing on optimizing diagnostic strategies for acute medical conditions.
Groundbreaking research combining fecal microbiota transplantation with biological therapies for inflammatory bowel disease treatment.
Exploring alternative treatment approaches for gastrointestinal conditions.
Preventive research targeting infantile spasm syndrome in high-risk children under one year of age, including those with tuberous sclerosis and vascular injuries.
Focused on improving outcomes in vulnerable pediatric populations.
Advanced research evaluating secukinumab treatment in combination with glucocorticoid therapy for giant cell arteritis management.
Investigating novel therapeutic approaches for vascular inflammation.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
